Jaffee EM - Search Results

1

Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?

Lutz ER, Jaffee EM. Lutz ER, et al. Among authors: jaffee em. Cancer Immunol Res. 2014 Jun;2(6):518-21. doi: 10.1158/2326-6066.CIR-14-0041. Epub 2014 May 2. Cancer Immunol Res. 2014. PMID: 24795140 Free PMC article. Review. No abstract available.

2

Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.

Golumbek PT, Azhari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM. Golumbek PT, et al. Among authors: jaffee em. Cancer Res. 1993 Dec 15;53(24):5841-4. Cancer Res. 1993. PMID: 8261390

3

Murine tumor antigens: is it worth the search?

Jaffee EM, Pardoll DM. Jaffee EM, et al. Curr Opin Immunol. 1996 Oct;8(5):622-7. doi: 10.1016/s0952-7915(96)80077-x. Curr Opin Immunol. 1996. PMID: 8902386 Free article. Review.

4

Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.

Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AH Jr, Piantadosi S, Dranoff G, Mulligan RC, Pardoll DM, Marshall FF. Simons JW, et al. Among authors: jaffee em. Cancer Res. 1997 Apr 15;57(8):1537-46. Cancer Res. 1997. PMID: 9108457 Free PMC article. Clinical Trial.

5

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM. Reilly RT, et al. Among authors: jaffee em. Cancer Res. 2000 Jul 1;60(13):3569-76. Cancer Res. 2000. PMID: 10910070

6

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM. Reilly RT, et al. Among authors: jaffee em. Cancer Res. 2001 Feb 1;61(3):880-3. Cancer Res. 2001. PMID: 11221874

7

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM. Machiels JP, et al. Among authors: jaffee em. Cancer Res. 2001 May 1;61(9):3689-97. Cancer Res. 2001. PMID: 11325840

8

A white paper: the product of a pancreas cancer think tank.

Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, Tempero MA. Kern S, et al. Cancer Res. 2001 Jun 15;61(12):4923-32. Cancer Res. 2001. PMID: 11406572 No abstract available.

9

HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.

Wolpoe ME, Lutz ER, Ercolini AM, Murata S, Ivie SE, Garrett ES, Emens LA, Jaffee EM, Reilly RT. Wolpoe ME, et al. Among authors: jaffee em. J Immunol. 2003 Aug 15;171(4):2161-9. doi: 10.4049/jimmunol.171.4.2161. J Immunol. 2003. PMID: 12902523

10

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH, Jaffee EM. Thomas AM, et al. Among authors: jaffee em. J Exp Med. 2004 Aug 2;200(3):297-306. doi: 10.1084/jem.20031435. J Exp Med. 2004. PMID: 15289501 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

346 results

Search Page

Filters